NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)
BERWYN, Pa., April 24, 2025 /PRNewswire/ -- Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., announced a partnership with Harrow (Nasdaq: HROW), a leading North American eyecare company, to launch an authorized generic of Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension), which treats and relieves bacterial eye infections.
Maxitrol® and generic equivalents had annual sales of $20.8 million in the U.S., according to IQVIA data, as of January 2025.
"Today marks the culmination of months of work to bring this exciting new authorized generic to the marketplace. This product is a great addition to our generic portfolio, providing patients another affordable prescription option," said Thomas Sammler, VP Commercial Operations.
For more information about Nordic Pharma, Inc. visit www.nordicpharmausa.com.
About Nordic Group B.V.Nordic Group B.V. is a privately owned, medium-size international pharmaceutical company which focuses on the development and commercialization of specialty products. Portfolio enhancement has been accomplished through targeted developments and focused acquisitions to build a foundation in Eye Care, Rheumatology and Women's Health. Nordic Group has established deep roots throughout Europe, and more recently, expanded outside of Europe with increased acquisitions worldwide.
Nordic Group is a part of SEVER Life Sciences, a holding company created in 2019 that brings together three diverse but complementary companies that offer a wide range of products, pharmaceutical development services and delivery technologies.
About Nordic Pharma, Inc.Nordic Pharma, Inc., subsidiary of Nordic Group B.V., is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
About HarrowHarrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.
Safe HarborThis press release contains forward-looking statements, including, without limitation, statements related to Nordic Group /Nordic Pharma's business developments and the implementation of Nordic Group /Nordic Pharma's strategic initiatives. Because these statements reflect Nordic Group /Nordic Pharma's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Nordic Group /Nordic Pharma's expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Nordic Group /Nordic Pharma, and other factors that could affect Nordic Group /Nordic Pharma's business and financial performance. Nordic Group /Nordic Pharma does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
ContactNordic Pharma, Inc.Kate PopovaContracts Administration LeadPhone Number: 610-285-1699ekaterina.popova@nordicpharma.com
Gail FeerrarDirector Sales and MarketingPhone: 610-285-7152gail.feerrar@nordicpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nordic-group-bv-through-its-subsidiary-nordic-pharma-inc-us-announces-launch-of-authorized-generic-of-maxitrol-neomycin-and-polymyxin-b-sulfates-and-dexamethasone-ophthalmic-suspension-302436485.html
SOURCE Nordic Pharma
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Citi Maintains Sell Rating on Enphase (ENPH), Lowers Price Target to $43
On June 5, analysts at Citi reiterated a 'Sell' rating on Enphase Energy, Inc. (NASDAQ:ENPH) but cut their price target to $43 from $47. The price adjustments follow mounting concerns about the future of the US residential solar market. Wind turbines against a backdrop of the sky, signifying the power of renewable energy. The analysts have raised concerns that the leading supplier of home energy solutions could come under pressure should there be changes in residential solar pricing. The Inflation Reduction Act is undergoing some changes. Proposed legislative changes include terminating 25D credits that could affect Enphase and other companies. The Citi analysts have warned that if the bill were to pass in its current form, solar installations could decline. The declines could hit highs of 75%, leading to business closures and slower innovation due to a reduced research and development budget. Assuming no changes are made to avert the slowdown, Citi analysts warn that Enphase Energy's EBITDA could decline by up to 60% next year. Likewise, the stock might end up trading in the high teens. Enphase Energy is an energy technology company specializing in designing, developing, manufacturing, and selling home energy solutions. It offers an intelligent platform that connects solar generation, energy storage, and management. While we acknowledge the potential of ENPH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and. Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
34 minutes ago
- Yahoo
DA Davidson Reiterates Buy Rating on MongoDB (MDB), Keeps PT
On June 5, DA Davidson analysts reiterated a 'Buy' rating on MongoDB Inc. (NASDAQ:MDB) stock and stuck with the $275 price target. The analysts asserted the rating and price target in response to the company's robust performance in the first quarter. Copyright: limonzest / 123RF Stock Photo MongoDB delivered Atlas and Non-Atlas revenue that topped analysts' expectations, contributing to a 19.2% year-over-year revenue increase. The company achieved non-GAAP earnings per share of $1.00, better than $0.66 expected. Revenue in the quarter totaled $549 million, above the $528.2 million expected. While Atlas consumption remained under pressure in April, it bounced back in May. On the other hand, Atlas's growth accelerated by 26% compared to 24% in the first quarter of last year. Following the better-than-expected first quarter results, MongoDB raised its fiscal year 2026 guidance due to some non-Atlas timing advantages realized in the quarter. It now expects full-year revenue to range between $2.25 billion and $2.29 billion, signaling confidence in continued growth. The company also increased its operating profit projections to affirm improvements in operational efficiency. DA Davidson reaffirmed the Buy rating buoyed by the company's strategic focus on operational efficiency. MongoDB is a company that develops and supports the MongoDB database, a popular NoSQL database known for its flexibility and scalability. It provides a multi-cloud developer data platform, including cloud-based services like MongoDB Atlas, and caters to a wide range of industries, including financial services, telecommunications, and healthcare. While we acknowledge the potential of MDB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and. Disclosure: None. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Dow Jones Futures: S&P 500 Nears Highs; What Tesla Investors Need To Focus On
The S&P 500 and Nasdaq are rallying toward record highs. Palantir and eToro are in buy areas. Tesla investors should focus on the TSLA chart.
